These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25955299)

  • 21. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
    Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo.
    Nishioka C; Ikezoe T; Yokoyama A
    Cancer Med; 2015 Sep; 4(9):1426-31. PubMed ID: 26139471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.
    Yang XH; Wang B; Cunningham JM
    BMC Med Genomics; 2015; 8 Suppl 2(Suppl 2):S6. PubMed ID: 26043758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?
    Shen Z; Chen L; Yang X; Zhao Y; Pier E; Zhang X; Yang X; Xiong Y
    Biochim Biophys Acta; 2013 Oct; 1833(10):2190-200. PubMed ID: 23688634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
    Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
    Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
    Zhang Q; Padi SK; Tindall DJ; Guo B
    Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
    Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
    Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
    Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
    Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
    Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
    Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation.
    Jarome TJ; Perez GA; Hauser RM; Hatch KM; Lubin FD
    J Neurosci; 2018 Aug; 38(35):7635-7648. PubMed ID: 30030400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of Sp1 and EZH2 in the regulation of LMX1A in cervical cancer cells.
    Lin WC; Yan MD; Yu PN; Li HJ; Kuo CC; Hsu CL; Lin YW
    Biochim Biophys Acta; 2013 Dec; 1833(12):3206-3217. PubMed ID: 24018208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.
    Floren M; Restrepo Cruz S; Termini CM; Marjon KD; Lidke KA; Gillette JM
    Oncogene; 2020 May; 39(19):3910-3925. PubMed ID: 32203165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
    Tagde A; Rajabi H; Stroopinsky D; Gali R; Alam M; Bouillez A; Kharbanda S; Stone R; Avigan D; Kufe D
    Oncotarget; 2016 Jun; 7(26):38974-38987. PubMed ID: 27259275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.
    Tanaka S; Miyagi S; Sashida G; Chiba T; Yuan J; Mochizuki-Kashio M; Suzuki Y; Sugano S; Nakaseko C; Yokote K; Koseki H; Iwama A
    Blood; 2012 Aug; 120(5):1107-17. PubMed ID: 22677129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
    Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
    Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.